摘要
目的观察针刺督脉组穴联合西药常规治疗缺血性脑卒中后认知功能障碍的临床疗效。方法将65例缺血性脑卒中后认知功能障碍患者采用完全随机化分组法分为对照组32例和治疗组33例,对照组在西医常规治疗基础上予奥拉西坦胶囊口服,治疗组在对照组治疗方法的基础上联合针刺督脉组穴治疗,治疗8周后比较2组治疗前后的简易智力状态检查量表(MMSE)评分、改良Barthel指数评定量表(MBI)评分及事件相关电位(P300)的潜伏期和波幅。结果治疗后2组MMSE评分、MBI评分及P300波幅明显升高,P300潜伏期明显缩短,与同组治疗前比较差异均有统计学意义(P<0.01),且治疗组改善更明显,与对照组治疗后比较差异均有统计学意义(P<0.05)。结论针刺督脉组穴联合西药常规治疗缺血性脑卒中后认知功能障碍疗效确切,能明显改善患者的认知功能及日常生活能力,值得临床推广应用。
Objective To observe the clinical efficacy of acupuncture at Du meridian group acupoints combined with conventional Western medicine in the treatment of cognitive dysfunction after ischemic stroke.Methods 65 patients with cognitive dysfunction after ischemic stroke were divided into control group(32 cases)and treatment group(33 cases)according to complete randomization grouping method.The control group was given oral oxacetam capsule on the basis of conventional Western medicine treatment,and the treatment group was given acupuncture at Du meridian group acupoints on the basis of treatment method of the control group.After 8 weeks of treatment,the scores of the mini-mental state examination(MMSE),the modified Barthel index rating scale(MBI),and the latency and amplitude of the event related potential(P300)were compared between the two groups before and after treatment.ResultsAfter treatment,MMSE score,MBI score and P300 amplitude of the two groups were significantly increased,P300 latency was significantly shortened,and the difference was statistically significant compared with the same group before treatment(P<0.01),meanwhile the improvement was more obvious in the treatment group,and the difference was statistically significant compared with the control group(P<0.05).Conclusion It has definite efficacy,can significantly improve the cognitive function and daily living ability of patients to apply acupuncture at Du meridian group acupoints combined with conventional Western medicine in the treatment of cognitive dysfunction after ischemic stroke,which is worthy of clinical promotion and application.
作者
柳星
卢会琴
程红亮
LIU Xing;LU Huiqin;CHENG Hongliang(Department of Encephalopathy,the Second Affiliated Hospital of Anhui University of Chinese Medicine,Hefei,Anhui,230061,China;Department of Oncology,Anhui Hospital of Integrated Traditional Chinese and Western Medicine,Hefeii,Anhui,230038,China)
出处
《甘肃中医药大学学报》
2022年第6期66-69,共4页
Journal of Gansu University of Chinese Medicine
基金
重大疾病治疗重点专科建设项目(财社[2022]45号)
安徽省自然科学基金青年基金项目(1908085QH370)
安徽省卫生健康委科研项目(AHWJ2021b034)。